Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
Anticancer Research
|
June 6, 1998
The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter
X Tong, D G Engehausen, C T Freund, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2010
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
J Sehouli, K Pietzner, P Harter, et al.
Gynecologic Oncology
|
December 6, 2001
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up
A Hasenburg, X W Tong, D C Fischer, et al.
Hybridoma
|
April 22, 1999
Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer
X Tong, D G Engehausen, C T Freund, et al.
Anticancer Research
|
July 23, 1998
Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients
T Levy, I Agoulnik, E N Atkinson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 28, 2002
Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer
A Hasenburg, D C Fischer, X-W Tong, et al.
Anticancer Research
|
June 6, 1998
Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy
X W Tong, D G Engehausen, R H Kaufman, et al.
Anti-Cancer Drugs
|
July 11, 1998
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma
A P Kudelka, A Hasenburg, C F Verschraegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Archives of Gynecology and Obstetrics
|
September 20, 2022
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database
M Bossart, H Plett, B Krämer, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
Anticancer Research
|
June 6, 1998
The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter
X Tong, D G Engehausen, C T Freund, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2010
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
J Sehouli, K Pietzner, P Harter, et al.
Gynecologic Oncology
|
December 6, 2001
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up
A Hasenburg, X W Tong, D C Fischer, et al.
Hybridoma
|
April 22, 1999
Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer
X Tong, D G Engehausen, C T Freund, et al.
Anticancer Research
|
July 23, 1998
Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients
T Levy, I Agoulnik, E N Atkinson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 28, 2002
Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer
A Hasenburg, D C Fischer, X-W Tong, et al.
Anticancer Research
|
June 6, 1998
Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy
X W Tong, D G Engehausen, R H Kaufman, et al.
Anti-Cancer Drugs
|
July 11, 1998
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma
A P Kudelka, A Hasenburg, C F Verschraegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Archives of Gynecology and Obstetrics
|
September 20, 2022
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database
M Bossart, H Plett, B Krämer, et al.
Page
of 7